SPARC Stock Overview
A biopharmaceutical company, engages in the research and development of pharmaceutical products in India and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
Sun Pharma Advanced Research Company Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₹203.40 |
| 52 Week High | ₹472.80 |
| 52 Week Low | ₹188.10 |
| Beta | 0.74 |
| 1 Month Change | -9.80% |
| 3 Month Change | -48.11% |
| 1 Year Change | 5.44% |
| 3 Year Change | -20.47% |
| 5 Year Change | 47.87% |
| Change since IPO | 133.26% |
Recent News & Updates
Recent updates
Sun Pharma Advanced Research (NSE:SPARC) Is In A Good Position To Deliver On Growth Plans
Jan 17
Sun Pharma Advanced Research Company Limited's (NSE:SPARC) Business Is Trailing The Industry But Its Shares Aren't
Nov 14Is Sun Pharma Advanced Research (NSE:SPARC) Using Too Much Debt?
Sep 05Here's Why We're Not At All Concerned With Sun Pharma Advanced Research's (NSE:SPARC) Cash Burn Situation
Jun 27Is Sun Pharma Advanced Research (NSE:SPARC) A Risky Investment?
Nov 23If You Had Bought Sun Pharma Advanced Research's (NSE:SPARC) Shares Three Years Ago You Would Be Down 57%
Feb 08
Do Institutions Own Sun Pharma Advanced Research Company Limited (NSE:SPARC) Shares?
Dec 14Shareholder Returns
| SPARC | IN Pharmaceuticals | IN Market | |
|---|---|---|---|
| 7D | -4.8% | -3.3% | -5.3% |
| 1Y | 5.4% | 47.6% | 34.5% |
Return vs Industry: SPARC underperformed the Indian Pharmaceuticals industry which returned 51.4% over the past year.
Return vs Market: SPARC underperformed the Indian Market which returned 45.3% over the past year.
Price Volatility
| SPARC volatility | |
|---|---|
| SPARC Average Weekly Movement | 7.6% |
| Pharmaceuticals Industry Average Movement | 6.0% |
| Market Average Movement | 6.7% |
| 10% most volatile stocks in IN Market | 9.7% |
| 10% least volatile stocks in IN Market | 4.3% |
Stable Share Price: SPARC's share price has been volatile over the past 3 months.
Volatility Over Time: SPARC's weekly volatility (8%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2006 | 407 | Anilkumar Raghavan | www.sparc.life |
Sun Pharma Advanced Research Company Limited, a biopharmaceutical company, engages in the research and development of pharmaceutical products in India and internationally. It develops products with a therapeutic focus on oncology, neurodegeneration, ophthalmology, dermatology, and Immunology. The company offers Elepsia XR, a formulation of levetiracetam that is an anti-epileptic agent to treat epilepsy disorder; Xelpros, a latanoprost ophthalmic emulsion for the treatment of open-angle glaucoma or ocular hypertension; and Phenobarbital injection for the treatment of neonatal seizures.
Sun Pharma Advanced Research Company Limited Fundamentals Summary
| SPARC fundamental statistics | |
|---|---|
| Market cap | ₹66.01b |
| Earnings (TTM) | -₹3.87b |
| Revenue (TTM) | ₹1.05b |
62.9x
P/S Ratio-17.0x
P/E RatioIs SPARC overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| SPARC income statement (TTM) | |
|---|---|
| Revenue | ₹1.05b |
| Cost of Revenue | ₹281.30m |
| Gross Profit | ₹768.90m |
| Other Expenses | ₹4.64b |
| Earnings | -₹3.87b |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -11.93 |
| Gross Margin | 73.21% |
| Net Profit Margin | -368.70% |
| Debt/Equity Ratio | 37.4% |
How did SPARC perform over the long term?
See historical performance and comparison